Literature DB >> 22933401

Oral gene application using chitosan-DNA nanoparticles induces transferable tolerance.

Katja Goldmann1, Stephan M Ensminger, Bernd M Spriewald.   

Abstract

Oral tolerance is a promising approach to induce unresponsiveness to various antigens. The development of tolerogenic vaccines could be exploited in modulating the immune response in autoimmune disease and allograft rejection. In this study, we investigated a nonviral gene transfer strategy for inducing oral tolerance via antigen-encoding chitosan-DNA nanoparticles (NP). Oral application of ovalbumin (OVA)-encoding chitosan-DNA NP (OVA-NP) suppressed the OVA-specific delayed-type hypersensitivity (DTH) response and anti-OVA antibody formation, as well as spleen cell proliferation following OVA stimulation. Cytokine expression patterns following OVA stimulation in vitro showed a shift from a Th1 toward a Th2/Th3 response. The OVA-NP-induced tolerance was transferable from donor to naïve recipient mice via adoptive spleen cell transfer and was mediated by CD4(+)CD25(+) T cells. These findings indicate that nonviral oral gene transfer can induce regulatory T cells for antigen-specific immune modulation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22933401      PMCID: PMC3491548          DOI: 10.1128/CVI.00186-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  48 in total

1.  Induction of antigen-specific regulatory T cells in the liver-draining celiac lymph node following oral antigen administration.

Authors:  Susanne Hultkrantz; Sofia Ostman; Esbjörn Telemo
Journal:  Immunology       Date:  2005-11       Impact factor: 7.397

Review 2.  Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells.

Authors:  Noriko M Tsuji; Akemi Kosaka
Journal:  Trends Immunol       Date:  2008-11       Impact factor: 16.687

Review 3.  Oral tolerance.

Authors:  Ana M C Faria; Howard L Weiner
Journal:  Immunol Rev       Date:  2005-08       Impact factor: 12.988

4.  Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophilia A mice.

Authors:  S S Dhadwar; J Kiernan; J Wen; G Hortelano
Journal:  J Thromb Haemost       Date:  2010-12       Impact factor: 5.824

5.  Expression of human insulin gene wrapped with chitosan nanoparticles in NIH3T3 cells and diabetic rats.

Authors:  Li Niu; Yan-cheng Xu; Hai-ying Xie; Zhe Dai; Hui-qin Tang
Journal:  Acta Pharmacol Sin       Date:  2008-11       Impact factor: 6.150

6.  A novel recombinant peptide containing only two T-cell tolerance epitopes of chicken type II collagen that suppresses collagen-induced arthritis.

Authors:  Caixia Xi; Liuxin Tan; Yeping Sun; Fei Liang; Nan Liu; Hong Xue; Yuan Luo; Fang Yuan; Yuying Sun; Yongzhi Xi
Journal:  Mol Immunol       Date:  2008-11-28       Impact factor: 4.407

7.  Gene therapy for type 1 diabetes mellitus in rats by gastrointestinal administration of chitosan nanoparticles containing human insulin gene.

Authors:  Li Niu; Yan-Cheng Xu; Zhe Dai; Hui-Qin Tang
Journal:  World J Gastroenterol       Date:  2008-07-14       Impact factor: 5.742

8.  Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles.

Authors:  Katherine Bowman; Rita Sarkar; Sanj Raut; Kam W Leong
Journal:  J Control Release       Date:  2008-06-27       Impact factor: 9.776

9.  Vasoactive intestinal polypeptide enhances oral tolerance by regulating both cellular and humoral immune responses.

Authors:  Y Wang; Y Mei; S Bao; L Xu
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

Review 10.  Chitosan nanoparticles for oral drug and gene delivery.

Authors:  Katherine Bowman; Kam W Leong
Journal:  Int J Nanomedicine       Date:  2006
View more
  9 in total

1.  Use of Polymeric Nanoparticle Platform Targeting the Liver To Induce Treg-Mediated Antigen-Specific Immune Tolerance in a Pulmonary Allergen Sensitization Model.

Authors:  Qi Liu; Xiang Wang; Xiangsheng Liu; Sanjan Kumar; Grant Gochman; Ying Ji; Yu-Pei Liao; Chong Hyun Chang; Wesley Situ; Jianqin Lu; Jinhong Jiang; Kuo-Ching Mei; Huan Meng; Tian Xia; Andre E Nel
Journal:  ACS Nano       Date:  2019-04-12       Impact factor: 15.881

2.  Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.

Authors:  Maowei Wang; Yan Yue; Chunsheng Dong; Xiaoyun Li; Wei Xu; Sidong Xiong
Journal:  Clin Vaccine Immunol       Date:  2013-09-11

3.  Chitosan-zein nano-in-microparticles capable of mediating in vivo transgene expression following oral delivery.

Authors:  Eric Farris; Deborah M Brown; Amanda E Ramer-Tait; Angela K Pannier
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

Review 4.  Immune Tolerance for Autoimmune Disease and Cell Transplantation.

Authors:  Xunrong Luo; Stephen D Miller; Lonnie D Shea
Journal:  Annu Rev Biomed Eng       Date:  2016-02-24       Impact factor: 9.590

Review 5.  Immunosuppressive and anti-inflammatory properties of engineered nanomaterials.

Authors:  A N Ilinskaya; M A Dobrovolskaia
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

Review 6.  Demystifying particle-based oral vaccines.

Authors:  Pedro Gonzalez-Cruz; Harvinder Singh Gill
Journal:  Expert Opin Drug Deliv       Date:  2021-07-06       Impact factor: 8.129

Review 7.  Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance.

Authors:  Takashi Kei Kishimoto; Roberto A Maldonado
Journal:  Front Immunol       Date:  2018-02-20       Impact factor: 7.561

Review 8.  General Characteristics, Biomedical and Dental Application, and Usage of Chitosan in the Treatment of Temporomandibular Joint Disorders: A Narrative Review.

Authors:  Marcin Derwich; Lukasz Lassmann; Katarzyna Machut; Agata Zoltowska; Elzbieta Pawlowska
Journal:  Pharmaceutics       Date:  2022-01-27       Impact factor: 6.321

Review 9.  Strategies to Use Nanoparticles to Generate CD4 and CD8 Regulatory T Cells for the Treatment of SLE and Other Autoimmune Diseases.

Authors:  David A Horwitz; Sean Bickerton; Antonio La Cava
Journal:  Front Immunol       Date:  2021-06-15       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.